AstraZeneca PLC (AZN)vsUnicycive Therapeutics Inc (UNCY)
AZN
AstraZeneca PLC
$195.15
-2.56%
HEALTHCARE · Cap: $284.30B
UNCY
Unicycive Therapeutics Inc
$5.73
-6.86%
HEALTHCARE · Cap: $156.96M
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
UNCY
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-0.4%
Fair Value
$194.37
Current Price
$195.15
$0.78 premium
Intrinsic value data unavailable for UNCY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : UNCY
The strongest argument for UNCY centers on Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : UNCY
The primary concerns for UNCY are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while UNCY is a value play — different risk/reward profiles.
UNCY carries more volatility with a beta of 1.79 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 21/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Unicycive Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical firm dedicated to developing groundbreaking therapies for kidney diseases, with a particular focus on hyperphosphatemia management. The company's proprietary drug candidates are designed to effectively regulate phosphorus levels, which are vital in treating renal disorders. With a robust commitment to research and development and strategic partnerships, Unicycive is positioned to drive innovation in nephrology. As it progresses through clinical trials, the company presents an attractive investment opportunity for institutional investors seeking high-impact solutions in the healthcare market.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?